TY - JOUR
T1 - The Assessment of Convalescent Plasma Efficacy against COVID-19
AU - Casadevall, Arturo
AU - Grossman, Brenda J.
AU - Henderson, Jeffrey P.
AU - Joyner, Michael J.
AU - Shoham, Shmuel
AU - Pirofski, Liise anne
AU - Paneth, Nigel
N1 - Funding Information:
A.C. was supported in part by NIH grants AI052733 , AI15207 , and HL059842 . L.P. is funded in part by a grant from the Mathers Foundation , NIH grant R01AI123654 , NIH grant R01AI143453 , and National Center for Advancing Translational Sciences (NCATS) grant 3UL1TR002556-04S1 . M.J.J. is supported in part by BARDA under contract 75A50120C00096 and National Heart, Lung, and Blood Institute (NHLBI) grant 5R35HL139854 . J.P.H. is supported in part by NIH grant DK111930 and The Longer Life Foundation .
Funding Information:
A.C. was supported in part by NIH grants AI052733, AI15207, and HL059842. L.P. is funded in part by a grant from the Mathers Foundation, NIH grant R01AI123654, NIH grant R01AI143453, and National Center for Advancing Translational Sciences (NCATS) grant 3UL1TR002556-04S1. M.J.J. is supported in part by BARDA under contract 75A50120C00096 and National Heart, Lung, and Blood Institute (NHLBI) grant 5R35HL139854. J.P.H. is supported in part by NIH grant DK111930 and The Longer Life Foundation. The seven authors constitute the leadership team of the COVID-19 Convalescent Plasma Project (ccpp19.org), and each contributed intellectually to the content and to the writing of this paper. B.J.G. is a member of the FDA Blood Products Advisory Committee. Any views or opinions expressed in this manuscript are the author's, based on her own scientific expertise and professional judgment; they do not necessarily represent either the views of the Blood Products Advisory Committee or the formal position of FDA, and they also do not bind or otherwise obligate or commit either the Blood Products Advisory Committee or the FDA to the views expressed.
Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2020/12/18
Y1 - 2020/12/18
N2 - Antibody-based therapy for infectious diseases predates modern antibiotics and, in the absence of other therapeutic options, was deployed early in the SARS-CoV-2 pandemic through COVID-19 convalescent plasma (CCP) administration. Although most studies have demonstrated signals of efficacy for CCP, definitive assessment has proved difficult under pandemic conditions, with rapid changes in disease incidence and the knowledge base complicating the design and implementation of randomized controlled trials. Nevertheless, evidence from a variety of studies demonstrates that CCP is as safe as ordinary plasma and strongly suggests that it can reduce mortality if given early and with sufficient antibody content.
AB - Antibody-based therapy for infectious diseases predates modern antibiotics and, in the absence of other therapeutic options, was deployed early in the SARS-CoV-2 pandemic through COVID-19 convalescent plasma (CCP) administration. Although most studies have demonstrated signals of efficacy for CCP, definitive assessment has proved difficult under pandemic conditions, with rapid changes in disease incidence and the knowledge base complicating the design and implementation of randomized controlled trials. Nevertheless, evidence from a variety of studies demonstrates that CCP is as safe as ordinary plasma and strongly suggests that it can reduce mortality if given early and with sufficient antibody content.
UR - http://www.scopus.com/inward/record.url?scp=85101838108&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101838108&partnerID=8YFLogxK
U2 - 10.1016/j.medj.2020.11.002
DO - 10.1016/j.medj.2020.11.002
M3 - Review article
C2 - 33363284
AN - SCOPUS:85101838108
SN - 2666-6359
VL - 1
SP - 66
EP - 77
JO - Med
JF - Med
IS - 1
ER -